SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Keap1-Nrf2-IN-20

Cat. No.:	HY-158055
Molecular Formula:	$C_{42}H_{67}N_{11}O_{19}$
Molecular Weight:	1030.04
Target:	Keap1-Nrf2
Pathway:	NF-κB
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Keap1-Nrf2-IN-20 (Compound ZC9) is an inhibitor for Keap-Nrf2 pathway with K_{D2} of 51 nM. Keap1-Nrf2-IN-20 exhibits good cell permeability, cell activity, and metabolic stability (serum $t_{1/2}$ > 24 h)[1].
In Vitro	Keap1-Nrf2-IN-20 (15-60 μM) inhibits expressions of TNF-α and IL-6 in LPS (HY-D1056)-induced inflammation in mouse peritoneal macrophages, exhibits anti-inflammatory efficacy[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Keap1-Nrf2-IN-20 (20-80 mg/kg, tail vein injection, single dose) attenuates LPS-induced acute lung injury in C57BL/6 mice model[1]. Keap1-Nrf2-IN-20 (56 mg/kg, iv, single dose) exhibits a satisfactory pharmacokinetic profils in Sprague Dawley rats, the half time ($T_{1/2}$), clearance rate (CL), area under curve (AUC) and apparent distribution volume (V) are 0.22 h, 3.90 L/h/kg, 14344.57 h·ng/mL and 1.26 L/kg, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LPS-induced acute lung injury in C57BL/6 mice model[1]
Dosage:	20-80 mg/kg
Administration:	tail vein injection, single dose
Result:	Maintained intact alveolar structure, reduced inflammatory cell infiltration, bleeding points or congestion.

REFERENCES

[1]. Zou J, et al., Cyclic Peptide Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury. J Med Chem. 2024 Mar 28;67(6):4889-4903.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA